tiprankstipranks
Seres Therapeutics (MCRB)
NASDAQ:MCRB

Seres Therapeutics (MCRB) Income Statement

824 Followers

Seres Therapeutics Income Statement

Last quarter (Q3 2023), Seres Therapeutics's total revenue was $310.00K, a decrease of -91.00% from the same quarter last year. In Q3, Seres Therapeutics's net income was $-48.89M. See Seres Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 127.24M$ 7.13M$ 143.86M$ 33.22M$ 34.51M$ 28.27M
Cost of Revenue
------
Gross Profit
$ 127.24M$ 7.13M$ 144.93M---
Operating Expense
$ 125.44M$ 253.62M$ -209.42M$ 121.34M$ 104.89M$ 128.55M
Operating Income
$ -132.55M$ -246.49M$ -64.49M$ -88.13M$ -70.38M$ -100.28M
Net Non Operating Interest Income Expense
$ -4.28M$ -2.96M$ -40.00K$ -1.98M$ 531.00K$ 1.17M
Other Income Expense
$ 225.00K$ 705.00K$ 1.04M$ 981.00K$ -426.00K$ 170.00K
Pretax Income
$ -138.10M$ -248.15M$ -65.58M$ -89.13M$ -70.28M$ -98.94M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -142.31M$ -248.15M$ -65.58M$ -89.13M$ -70.28M$ -98.94M
Basic EPS
$ -1.09$ -2.31$ -0.72$ -1.12$ -1.24$ -2.43
Diluted EPS
$ -1.09$ -2.31$ -0.72$ -1.12$ -1.24$ -2.43
Basic Average Shares
$ 489.94M$ 108.08M$ 91.70M$ 79.79M$ 56.65M$ 40.74M
Diluted Average Shares
$ 492.07M$ 108.08M$ 91.70M$ 79.79M$ 56.65M$ 40.74M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 125.44M$ 253.62M$ -209.42M$ 121.34M$ 104.89M$ 128.55M
Net Income From Continuing And Discontinued Operation
$ -141.27M$ -250.16M$ -65.58M$ -89.13M$ -70.28M$ -98.94M
Normalized Income
$ -38.62M$ -196.04M-$ -89.13M$ -68.79M$ -98.94M
Interest Expense
---$ 2.92M$ 502.00K$ 0.00
EBIT
$ -129.52M$ -242.13M$ -65.54M$ -86.20M$ -69.78M$ -98.94M
EBITDA
$ -122.62M$ -234.11M$ -56.57M$ -79.63M$ -62.17M$ -91.08M
Currency in USD

Seres Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis